Acetyl-CTTN (K235) Antibody

What is Acetyl-CTTN (K235) Antibody and what cellular processes does it help investigate?

Acetyl-CTTN (K235) antibody is a rabbit polyclonal antibody that specifically detects endogenous levels of cortactin protein when acetylated at lysine 235. This antibody is designed to recognize the post-translational modification of cortactin, which plays critical roles in multiple cellular processes including actin cytoskeleton organization, cell shape determination, and lamellipodial formation . The antibody is generated using a synthesized acetyl-peptide derived from the internal region of human cortactin around the acetylation site of K235 . It enables researchers to investigate how cortactin acetylation affects its numerous functions, particularly in intracellular protein transport, endocytosis, and modulation of potassium channels at the cell membrane .

What are the validated applications for Acetyl-CTTN (K235) Antibody in research protocols?

According to multiple sources, Acetyl-CTTN (K235) antibody has been validated for Western Blot (WB) and ELISA applications . For Western Blotting, the recommended dilution range is 1:500-1:2000, while ELISA applications typically use a 1:10000 dilution . The antibody demonstrates reactivity across human, mouse, and rat samples, making it versatile for comparative studies across these species . Researchers should note that this antibody is strictly for research use only and not for diagnostic or therapeutic applications, which limits its use to experimental contexts .

What optimization strategies improve detection sensitivity with Acetyl-CTTN (K235) Antibody?

When optimizing protocols using Acetyl-CTTN (K235) antibody, researchers should consider several factors:

• Sample preparation: Proper cell lysis techniques that preserve protein modifications are essential; phosphatase and deacetylase inhibitors should be included in lysis buffers to prevent loss of the acetylation signal.

• Protein loading: Standardize protein concentrations (typically 20-50 μg per lane for cell lysates) and confirm using control antibodies that detect total cortactin.

• Blocking conditions: A 5% BSA solution in TBST is often more effective than milk-based blockers, as milk can contain phosphatases that might affect detection of modified proteins.

• Antibody incubation: Overnight incubation at 4°C with the primary antibody often yields better results than shorter incubations at room temperature.

• Detection method: Enhanced chemiluminescence (ECL) systems with longer exposure times may be necessary to detect low abundance acetylated cortactin .

The antibody's specificity for acetylated K235 makes it imperative to include proper controls, such as unmodified cortactin samples, to validate signal specificity.

How does cortactin acetylation at K235 regulate cytoskeletal dynamics?

Cortactin acetylation at K235 significantly alters its functional properties in cytoskeletal organization. Acetylation at this residue has been shown to:

• Reduce cortactin's ability to bind F-actin, thereby decreasing its capacity to cross-link actin filaments

• Alter interactions with binding partners involved in actin polymerization

• Affect cortactin's role in focal adhesion assembly and turnover

These modifications impact the protein's ability to regulate cell migration, lamellipodial persistence, and cell shape changes . In functional contexts, cortactin works in complex with ABL1 and MYLK to regulate cortical actin-based cytoskeletal rearrangement, which is critical to endothelial cell barrier enhancement in response to sphingosine 1-phosphate (S1P) . The acetylation state of K235 can therefore serve as a molecular switch that modulates these interactions and subsequent cytoskeletal rearrangements.

What is the relationship between cortactin K235 acetylation and endocytosis pathways?

Cortactin plays a crucial role in intracellular protein transport and endocytosis, particularly in receptor-mediated endocytosis via clathrin-coated pits . Acetylation at K235 affects cortactin's ability to:

• Interact with dynamin, a GTPase essential for vesicle scission during endocytosis

• Regulate the assembly and disassembly of the actin cytoskeleton at endocytic sites

• Modulate the levels of potassium channels present at the cell membrane

Research suggests that acetylation status at K235 can be dynamically regulated to control cortactin's participation in these processes. When studying endocytic pathways using Acetyl-CTTN (K235) antibody, researchers should design experiments that capture these dynamic processes, potentially using pulse-chase approaches or live cell imaging in conjunction with fixed-cell immunodetection .

How is cortactin acetylation implicated in neuronal development and function?

Cortactin has been established as a key player in neuronal development, particularly in:

• Regulation of neuron morphology

• Axon growth guidance

• Formation of neuronal growth cones

• Regulation of neuronal spine density (through interaction with CTTNBP2)

The acetylation state of cortactin at K235 likely serves as a regulatory mechanism for these functions. When designing studies to investigate neuronal development using Acetyl-CTTN (K235) antibody, researchers should consider developmental timepoints, specific neuronal subtypes, and subcellular localization analysis to determine how acetylation patterns change during neuronal maturation and in response to various stimuli.

What controls should be implemented to validate Acetyl-CTTN (K235) Antibody specificity?

To ensure experimental rigor when using Acetyl-CTTN (K235) antibody, researchers should implement multiple validation approaches:

• Peptide competition assay: Pre-incubating the antibody with the immunizing acetylated peptide should abolish specific signal.

• Acetylation/deacetylation controls: Treatment of samples with deacetylase inhibitors (e.g., trichostatin A, nicotinamide) should increase signal, while treatment with recombinant deacetylases should reduce signal.

• CRISPR/Cas9-generated K235R mutants: Creating cell lines with a lysine-to-arginine mutation at position 235 (preventing acetylation) provides an excellent negative control.

• Mass spectrometry validation: Parallel analysis of immunoprecipitated samples using mass spectrometry can confirm the presence of acetylation at K235 and identify potential cross-reactive sites .

• Antibody specificity assessment: The antibody has been shown to detect endogenous levels of cortactin protein only when acetylation is present at K235, making it specific for this modification .

How can mass spectrometry complement antibody-based detection of cortactin acetylation?

Mass spectrometry (MS) provides complementary information to antibody-based detection of cortactin acetylation:

• Site-specific validation: MS can confirm acetylation specifically at K235 and identify additional acetylation sites that may be functionally relevant.

• Quantitative analysis: MS enables quantification of the stoichiometry of acetylation at K235 relative to unmodified cortactin.

• Detection of co-occurring modifications: MS can identify other post-translational modifications that may occur in proximity to or in conjunction with K235 acetylation.

• Unbiased discovery: While antibodies detect known sites, MS can reveal novel acetylation sites on cortactin.

A typical MS workflow for studying cortactin acetylation includes immunoprecipitation with either total cortactin or acetyl-lysine antibodies, followed by digestion with proteases like LysC and trypsin, as mentioned in search result . Samples are then reduced with dithiothreitol (DTT), alkylated with iodoacetamide (IAA), and analyzed using techniques such as higher-energy collisional dissociation (HCD) on instruments like Q Exactive HF Orbitrap mass spectrometers .

What methodologies can distinguish between different acetylation sites on cortactin?

Distinguishing between multiple acetylation sites on cortactin requires sophisticated approaches:

• Site-specific antibodies: Using antibodies like Acetyl-CTTN (K235) that recognize specific acetylation sites.

• Mutational analysis: Generating cortactin constructs with lysine-to-arginine or lysine-to-glutamine mutations at specific sites to prevent or mimic acetylation, respectively.

• MS/MS fragmentation patterns: Tandem mass spectrometry can precisely locate acetylation sites based on fragmentation patterns of peptides.

• Acetylation site-specific enzymes: Some deacetylases show preference for specific sites, which can be leveraged to manipulate acetylation at particular residues.

• Targeted proteomics: Selected reaction monitoring (SRM) or parallel reaction monitoring (PRM) MS approaches can specifically track peptides containing K235 and other acetylation sites with high sensitivity.

For comprehensive acetylation profiling, researchers might consider combining these approaches with temporal studies that reveal the dynamics of acetylation at different sites under various cellular conditions.

How is cortactin acetylation associated with cancer progression?

Research into post-translational acetylation has revealed important connections to cancer biology, which can be investigated using Acetyl-CTTN (K235) antibody:

• Invasive potential: Altered cortactin acetylation patterns may affect cancer cell migration and invasion through modulation of actin cytoskeleton dynamics.

• Metastatic capacity: Changes in cortactin's ability to regulate focal adhesion assembly and turnover due to acetylation status may impact metastatic processes.

• Signaling pathway integration: Cortactin acetylation status may be regulated downstream of oncogenic signaling pathways.

While the search results don't directly address cortactin K235 acetylation in cancer, they do indicate that K235 acetylation of another protein (ALKBH5) is upregulated in cancers and promotes tumorigenesis . This suggests that K235 acetylation could be a functionally significant modification across multiple proteins in cancer contexts, warranting investigation of cortactin K235 acetylation in cancer models as well.

What is the potential role of cortactin acetylation in autoimmune conditions?

Acetylation of proteins has emerged as an important factor in autoimmune conditions, particularly in rheumatoid arthritis (RA):

• Antigenic potential: Acetylated proteins can function as antigens that breach tolerance towards post-translationally modified (PTM) self-proteins .

• Cross-reactivity with bacterial proteins: Recent research demonstrates that acetylated bacterial proteins can be recognized by human anti-modified protein antibodies (AMPAs) and can induce AMPA responses in animal models .

• Multi-reactive antibody responses: Antibodies targeting proteins with various PTM residues (citrulline, homocitrulline, acetyllysine) tend to be present simultaneously in sera of RA patients and demonstrate cross-reactivity at both monoclonal and polyclonal levels .

While the search results don't specifically address cortactin acetylation in autoimmune conditions, the principles of protein acetylation as an immunogenic modification suggest potential relevance. Researchers investigating autoimmune phenomena could use Acetyl-CTTN (K235) antibody to examine whether cortactin acetylation contributes to autoantigen formation in models of autoimmune disease.

How can Acetyl-CTTN (K235) Antibody be used in neurodegenerative disease research?

Given cortactin's roles in neuronal morphology, axon growth, and neuronal spine density regulation , Acetyl-CTTN (K235) antibody could be valuable in neurodegenerative disease research:

• Synaptic integrity: Monitoring cortactin acetylation in models of neurodegenerative diseases may reveal changes in synaptic structure maintenance.

• Axonal transport: Investigating how cortactin acetylation affects its involvement in intracellular protein transport could illuminate defects in axonal transport common in neurodegenerative conditions.

• Neuroinflammation: Examining whether acetylated cortactin contributes to inflammatory processes in neurodegenerative diseases.

• Therapeutic interventions: Testing whether compounds that modulate cortactin acetylation affect disease progression in models of neurodegeneration.

Researchers could design experiments comparing cortactin K235 acetylation patterns in healthy versus diseased neural tissues, or examine how disease-associated stressors affect cortactin acetylation dynamics in neuronal cultures.

How should researchers address inconsistent results with Acetyl-CTTN (K235) Antibody?

When encountering variability in Acetyl-CTTN (K235) antibody results, consider these troubleshooting approaches:

• Sample preparation optimization:

  • Ensure consistent and complete lysis (sonication may improve extraction)

  • Add fresh protease and deacetylase inhibitors to all buffers

  • Maintain samples at 4°C throughout processing

• Antibody validation checks:

  • Verify antibody lot consistency with manufacturer's validation data

  • Consider testing the antibody on positive control samples known to contain acetylated cortactin

  • Test the antibody's specificity using peptide competition assays

• Technical adjustments:

  • Optimize blocking conditions (BSA vs. milk-based blockers)

  • Adjust antibody concentration and incubation time

  • Test different detection systems (HRP-conjugated vs. fluorescent secondary antibodies)

• Biological variables:

  • Control for cell confluency, as contact inhibition may affect cortactin acetylation

  • Standardize culture conditions, as serum factors can influence acetylation

  • Consider cell cycle effects on cortactin localization and modification

The antibody has been affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen, which should enhance its specificity for the K235 acetylation site .

What novel research applications are emerging for Acetyl-CTTN (K235) Antibody?

Emerging applications for Acetyl-CTTN (K235) antibody include:

• Single-cell analysis: Combining with flow cytometry or mass cytometry (CyTOF) to examine cortactin acetylation heterogeneity within cell populations.

• Live-cell imaging: Development of acetylation-specific intrabodies or nanobodies based on Acetyl-CTTN (K235) antibody sequences for real-time visualization of acetylation dynamics.

• Super-resolution microscopy: Using Acetyl-CTTN (K235) antibody with techniques like STORM or PALM to visualize nanoscale organization of acetylated cortactin in cellular structures.

• Proximity labeling: Combining with BioID or APEX2 approaches to identify proteins that specifically interact with acetylated cortactin.

• CRISPR screens: Using Acetyl-CTTN (K235) antibody readouts to identify genes that regulate cortactin acetylation in genome-wide screens.

These applications extend beyond traditional Western blot and ELISA techniques , enabling more sophisticated investigation of cortactin acetylation biology.

How can Acetyl-CTTN (K235) Antibody be used in conjunction with other research tools?

Integrating Acetyl-CTTN (K235) antibody with complementary research tools creates powerful experimental paradigms:

• Combination with total cortactin antibodies: Parallel detection allows calculation of the acetylated proportion of the total cortactin pool.

• Integration with phospho-specific antibodies: Since cortactin undergoes multiple post-translational modifications, detecting acetylation alongside phosphorylation can reveal modification crosstalk.

• Chromatin immunoprecipitation (ChIP): Though cortactin is primarily cytoplasmic, nuclear functions have been reported, making ChIP a potential application to investigate nuclear roles of acetylated cortactin.

• Paired with actin visualization: Combining Acetyl-CTTN (K235) antibody immunofluorescence with phalloidin staining can reveal how acetylation affects cortactin's co-localization with F-actin structures.

• Multi-omics approaches: Using the antibody for proteomics studies that are then integrated with transcriptomics or metabolomics data to place cortactin acetylation in broader cellular contexts.

For instance, researchers investigating endocytosis might combine Acetyl-CTTN (K235) antibody with markers of clathrin-coated pits to examine how acetylation affects cortactin's recruitment to endocytic sites .